secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001104659-23-070107
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix reports positive 12-month Phase 1 data for OTX-TKI in wet AMD
--------------------------------------------------------------------------------

- 12-month data showed OTX-TKI maintained controlled wet AMD comparable to aflibercept, with mean BCVA change of -1.0 letters vs +2.0 letters.
- 89% reduction in treatment burden observed in OTX-TKI subjects at 12 months; 60% were rescue-free up to Month 12.
- No drug-related ocular or systemic serious adverse events in OTX-TKI arm; one SAE of endophthalmitis related to injection procedure.
- Company plans to initiate a pivotal trial in wet AMD as early as Q3 2023, subject to obtaining necessary financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923070107/0001104659-23-070107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923070107/tm2318436d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-070107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer